Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114893 · ClinicalTrials.gov registry record · Phase 2
Travoprost Five Day Posology Study
A Phase 2 study of Ocular Hypertension and Open Angle Glaucoma (OAG), sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01114893 is a Phase 2 study of Ocular Hypertension and Open Angle Glaucoma (OAG) that has completed, run by Alcon Research. The registered enrollment target is 60 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01114893, a Phase 2 study of Ocular Hypertension and Open Angle Glaucoma (OAG), has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.
Conditions Studied
Interventions
- DRUG Travoprost 0.004%
- DRUG Travoprost Vehicle
- DRUG Travoprost (Groups A, B and C)
Study Locations (1)
Texas
- Contact Alcon Call Center For Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01114893
The ClinicalTrials.gov registry entry for NCT01114893 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (78% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Travoprost 0.004% is the first listed.
NCT01114893 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01114893 about?
NCT01114893 is a clinical study titled "Travoprost Five Day Posology Study". The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.
What is the current status of trial NCT01114893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2010-04.
What conditions does trial NCT01114893 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma (OAG).
What interventions are being tested in trial NCT01114893?
The interventions under investigation include: Travoprost 0.004% (DRUG), Travoprost Vehicle (DRUG), Travoprost (Groups A, B and C) (DRUG).
Who is sponsoring clinical trial NCT01114893?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01114893 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
-
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.